Browse MCM2

Summary
SymbolMCM2
Nameminichromosome maintenance complex component 2
Aliases D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00493 MCM2/3/5 family
PF12619 Mini-chromosome maintenance protein 2
PF14551 MCM N-terminal domain
PF17207 MCM OB domain
Function

Acts as component of the MCM2-7 complex (MCM complex) which is the putative replicative helicase essential for 'once per cell cycle' DNA replication initiation and elongation in eukaryotic cells. The active ATPase sites in the MCM2-7 ring are formed through the interaction surfaces of two neighboring subunits such that a critical structure of a conserved arginine finger motif is provided in trans relative to the ATP-binding site of the Walker A box of the adjacent subunit. The six ATPase active sites, however, are likely to contribute differentially to the complex helicase activity. Required for the entry in S phase and for cell division. Plays a role in terminally differentiated hair cells development of the cochlea and induces cells apoptosis.

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0006260 DNA replication
GO:0006261 DNA-dependent DNA replication
GO:0006268 DNA unwinding involved in DNA replication
GO:0006270 DNA replication initiation
GO:0006323 DNA packaging
GO:0006333 chromatin assembly or disassembly
GO:0006334 nucleosome assembly
GO:0031497 chromatin assembly
GO:0032392 DNA geometric change
GO:0032508 DNA duplex unwinding
GO:0034728 nucleosome organization
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0065004 protein-DNA complex assembly
GO:0070670 response to interleukin-4
GO:0071103 DNA conformation change
GO:0071353 cellular response to interleukin-4
GO:0071824 protein-DNA complex subunit organization
Molecular Function GO:0003678 DNA helicase activity
GO:0003688 DNA replication origin binding
GO:0004386 helicase activity
GO:0042393 histone binding
Cellular Component GO:0000781 chromosome, telomeric region
GO:0000784 nuclear chromosome, telomeric region
GO:0000785 chromatin
GO:0000808 origin recognition complex
GO:0005664 nuclear origin of replication recognition complex
GO:0042555 MCM complex
GO:0044454 nuclear chromosome part
GO:0098687 chromosomal region
> KEGG and Reactome Pathway
 
KEGG hsa03030 DNA replication
hsa04110 Cell cycle
Reactome R-HSA-176187: Activation of ATR in response to replication stress
R-HSA-68962: Activation of the pre-replicative complex
R-HSA-68867: Assembly of the pre-replicative complex
R-HSA-1640170: Cell Cycle
R-HSA-69620: Cell Cycle Checkpoints
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-69306: DNA Replication
R-HSA-69002: DNA Replication Pre-Initiation
R-HSA-69190: DNA strand elongation
R-HSA-69206: G1/S Transition
R-HSA-69481: G2/M Checkpoints
R-HSA-68874: M/G1 Transition
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-68949: Orc1 removal from chromatin
R-HSA-69304: Regulation of DNA replication
R-HSA-69300: Removal of licensing factors from origins
R-HSA-69242: S Phase
R-HSA-69052: Switching of origins to a post-replicative state
R-HSA-69239: Synthesis of DNA
R-HSA-176974: Unwinding of DNA
Summary
SymbolMCM2
Nameminichromosome maintenance complex component 2
Aliases D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MCM2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolMCM2
Nameminichromosome maintenance complex component 2
Aliases D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MCM2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolMCM2
Nameminichromosome maintenance complex component 2
Aliases D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MCM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.2710.427
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3050.865
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2510.859
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8580.0993
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.8360.644
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.8970.722
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1410.708
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0910.951
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2690.86
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.4520.704
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.4480.798
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5812.08e-05
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MCM2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.511.8-2.31
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMCM2
Nameminichromosome maintenance complex component 2
Aliases D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MCM2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMCM2
Nameminichromosome maintenance complex component 2
Aliases D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MCM2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MCM2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMCM2
Nameminichromosome maintenance complex component 2
Aliases D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MCM2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMCM2
Nameminichromosome maintenance complex component 2
Aliases D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MCM2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMCM2
Nameminichromosome maintenance complex component 2
Aliases D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MCM2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMCM2
Nameminichromosome maintenance complex component 2
Aliases D3S3194; KIAA0030; BM28; cdc19; mitotin; CDCL1; minichromosome maintenance deficient (S. cerevisiae) 2 (mito ......
Chromosomal Location3q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MCM2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.